Overview

Study Evaluating BLI-489 and Piperacillin in Healthy Subjects

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how BLI-489 and piperacillin interact when given together to healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
BLI-489
Piperacillin